UNSPSC 51412700: Vasodilator furans

Vasodilator drugs made from compounds with a 5-membered ring of four carbons and an oxygen.

UNSPSC 51412700 Vasodilator furans is a Class code under which state and local governments procure emergency pharmaceuticals and OTC medications for use by fire rescue, hospital, and health agency personnel. Recent solicitations show buying offices sourcing specific medication line items—epinephrine, labetalol, adenosine, and diltiazem formulations—with firm pricing, delivery within tight timeframes (often ten calendar days), and minimum shelf-life warranties (typically six to nine months from acceptance). Issuing bodies span municipal fire departments, state health commissions, and multi-state cooperative purchasing alliances. The City of Tampa's Purchasing Department and the Texas Health and Human Services Commission are recent active buyers; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers a standing RFP for generic pharmaceuticals distributed across state and local facilities in multiple jurisdictions.

Activity clusters in Florida, Texas, and Minnesota, with MMCAP extending reach to Oregon and other participating states. The City of Tampa issued ITB 26P00188 on April 24, 2026 for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; awards go to the lowest responsive, responsible bidder, with a Small Local Business Enterprise sheltered-market 5 percent bid discount available. The Minnesota Multistate Cooperative Purchasing Alliance posted RFP S1070000015802 on January 20, 2026 with a March 26, 2026 due date for generic multi-source pharmaceuticals and OTC products, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with contract effectiveness July 1, 2026 and a two-year initial term. Vendors must maintain compliance with cGMP, DSCSA, FDA requirements, and comprehensive insurance (general liability $5,000,000 per occurrence). The Texas HHS Commission issued an exploratory RFI (HHS0017013) in March 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs; this precedes formal competitive solicitation and gathers market intelligence without committed budget or award timeline.